Radiation plus drug cocktail shows promise for resistant lung cancer

NCT ID NCT06775743

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding precise radiation (SBRT) to a four-drug combination (sintilimab, bevacizumab, and chemotherapy) can help people with advanced EGFR-mutant lung cancer whose tumors have stopped responding to standard targeted therapy. About 53 participants will receive the drug combo first, then personalized radiation to any remaining tumors. Researchers will measure how long the cancer stays under control and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sintilimab, bevacizumab, platinum-doublet chemotherapy, and stereotactic body radiotherapy
What this could lead to: If it works, this could offer a new treatment option for people with a specific type of advanced lung cancer that has stopped responding to standard pills.
What could go wrong: This is a small, early-phase study (53 people) with no control group, so results may not apply broadly. The combination therapy can cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR MUTATION POSITIVE ADVANCED NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR MUTATION POSITIVE ADVANCED NON SMALL CELL LUNG CANCER NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.